CTLT - Catalent, Inc.
| Previous Close | 59.60 |
| Open | 59.85 |
| Bid | 60.48 x 1000 |
| Ask | 60.49 x 1800 |
| Day's Range | 59.74 - 60.61 |
| 52 Week Range | 39.09 - 68.78 |
| Volume | 1,838,203 |
| Avg. Volume | 858,621 |
| Market Cap | 9.438B |
| Beta (5Y Monthly) | 1.75 |
| PE Ratio (TTM) | 72.31 |
| EPS (TTM) | 0.84 |
| Earnings Date | May 04, 2020 - May 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 70.29 |
- GuruFocus.com
Top Insider Buys Highlight for the Week of Feb. 14
Insiders load up on Salesforce.com, Ford, Catalent and PPD Continue reading...
- Thomson Reuters StreetEvents
Edited Transcript of CTLT earnings conference call or presentation 3-Feb-20 1:15pm GMT
Q2 2020 Catalent Inc Earnings Call
- Business Wire
Catalent Completes Acquisition of MaSTherCell
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had completed its acquisition of MaSTherCell Global Inc., positioning Catalent as a premier technology, development and manufacturing partner for innovators of advanced biotherapeutics.
- Simply Wall St.
US$70.88 - That's What Analysts Think Catalent, Inc. Is Worth After These Results
Catalent, Inc. (NYSE:CTLT) investors will be delighted, with the company turning in some strong numbers with its...
- Benzinga
The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences ...
- Business Wire
Catalent, Inc. Announces Pricing of Public Offering of Common Stock
Catalent, Inc. ("Catalent") (NYSE:CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced the pricing of an underwritten public offering (the "Offering") of shares of its common stock, which is expected to result in gross proceeds of approximately $500 million, before deducting estimated offering expenses. The underwriters may offer the shares of common stock from time to time to purchasers directly or through agents, or through brokers in brokerage transactions on the New York Stock Exchange, in the over-the-counter market, or to dealers in negotiated transactions or in a combination of such methods of sale or otherwise at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. In connection with the Offering, Catalent has granted the underwriters an option for 30 days to purchase up to an additional $75 million of shares of its common stock. Subject to customary closing conditions, the Offering is expected to settle and close on or about February 6, 2020.
- Business Wire
Catalent, Inc. Announces Public Offering of Common Stock
Catalent, Inc. ("Catalent") (NYSE:CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has launched an underwritten public offering (the "Offering") of $500 million of its common stock. In connection with the Offering, Catalent intends to grant the underwriters an option for 30 days to purchase up to $75 million of additional shares of its common stock.
- Benzinga
Catalent To Buy Cell Therapy CDMO MasTherCell For $315M
Catalent Inc (NYSE: CTLT ), a contract development and manufacturing organization, or CDMO, that provides services for the development of drugs, biologics, gene therapies and consumer health products, ...
- Zacks
Catalent (CTLT) Matches Q2 Earnings Estimates
Catalent (CTLT) delivered earnings and revenue surprises of 0.00% and 3.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Catalent, Inc. Reports Second Quarter Fiscal 2020 Results
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced financial results for the second quarter of fiscal year 2020, which ended December 31, 2019, as well as its agreement to acquire MaSTherCell Global, Inc., a leading cell therapy development and manufacturing provider with facilities in Belgium and Texas. With the acquisition of MaSTherCell , Catalent is further expanding its advanced biotechnology platform within its Biologics business. Catalent is issuing a separate press release today that provides further details on this acquisition.
- Business Wire
Catalent To Acquire Leading Cell Therapy Company MaSTherCell Global for $315 Million, Creating an Industry-Leading Cell & Gene Therapy Platform
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and MaSTherCell Global, Inc., a technology-focused cell and gene therapy contract development and manufacturing organization to leading cell therapy innovators, today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. (NASDAQ:ORGS), for an aggregate of $315 million in cash, subject to a customary adjustments.
- Zacks
Catalent (CTLT) Reports Next Week: What You Should Expect
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Calculating The Fair Value Of Catalent, Inc. (NYSE:CTLT)
In this article we are going to estimate the intrinsic value of Catalent, Inc. (NYSE:CTLT) by taking the expected...
- Business Wire
Catalent Further Strengthens Biologics Business with Key Senior Appointments
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced the appointment of Karen Flynn as President of Biologics and Chief Commercial Officer. Ms. Flynn has also joined the company’s Executive Leadership Team and will report to Alessandro Maselli, Catalent’s President and Chief Operating Officer. Ms. Flynn takes on the role previously held by Mr. Barry Littlejohns, who will be retiring.
- Business Wire
Catalent, Inc. Announces Second Quarter Fiscal Year 2020 Earnings Conference Webcast
Catalent, Inc. (NYSE: CTLT) ("Catalent"), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the second quarter of fiscal year 2020 ended December 31, 2019, before the market open on Monday, February 3, 2020. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET on the same day.
- Insider Monkey
2019 Review: Top Hedge Fund Stocks vs. Catalent Inc (CTLT)
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- Business Wire
Catalent, Inc. to Present at the 38th Annual J.P. Morgan Health Care Conference
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that John Chiminski, Chair & Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference at 9:30 a.m. PT on Monday, January 13, 2020 in San Francisco, CA.
- Simply Wall St.
How Many Catalent, Inc. (NYSE:CTLT) Shares Did Insiders Buy, In The Last Year?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- Insider Monkey
Hedge Funds Piled Into Catalent Inc (CTLT) Just In Time
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
- Simply Wall St.
With EPS Growth And More, Catalent (NYSE:CTLT) Is Interesting
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
- Thomson Reuters StreetEvents
Edited Transcript of CTLT earnings conference call or presentation 5-Nov-19 1:15pm GMT
Q1 2020 Catalent Inc Earnings Call
- TipRanks
3 Monster Growth Stocks That Are Still Undervalued
For growth stocks, Wall Street pros suggest looking at the bigger picture. We mean taking a step back and searching for names capable of rewarding investors for years to come rather than in just the short-term. However, finding these stocks with explosive growth prospects isn’t always easy.That’s where TipRanks.com comes in. Using the platform’s in-depth market data, we were able to zero in on 3 stocks set to see huge gains in the long-run. Having earned enough support from the Street’s analysts in the last three months, all of these names have “Strong Buy” consensus ratings.If that wasn’t captivating enough, analysts note that each of the stocks’ strong growth narratives aren’t fully factored into their share prices, representing a compelling entry point.With this in mind, let’s dive in. Avalara, Inc. (AVLR) Avalara offers customers automated and cloud-based software to make it easier to comply with ever-changing tax laws. With another solid quarterly performance under its belt and an already posted year-to-date gain of 128%, analysts believe AVLR is still undervalued as it’s right on track to deliver massive returns.During its most recent quarter, AVLR was able to report a revenue and earnings beat thanks to substantial customer additions. We’re talking 810 new customers added vs J.P. Morgan analyst Sterling Auty’s estimate of 300. Not to mention the company reached an all-time high net retention rate of 113% and management guided around 25% revenue growth for 2020\. While the results represented a loss, Auty tells investors not to fear as AVLR is just getting started. “We think the stock still has room to move higher driven by these secular growth factors and a valuation that is below many other premium names,” he commented. The five-star analyst adds that its 2020 revenue guidance “likely provides ample opportunity to under promise and over deliver”. As a result, Auty kept his Buy rating and $104 price target. This target conveys his confidence in AVLR’s ability to climb 46% higher over the next twelve months. (To watch Auty’s track record, click here) Like Auty, the rest of the Street has high hopes for AVLR. As 100% of the analysts that have published ratings in the last three months were bullish, AVLR is a ‘Strong Buy’. Additionally, its $98 average price target indicates 37% upside potential. (See Avalara stock analysis on TipRanks) The Trade Desk, Inc. (TTD)This year has seen Trade Desk cement its status as a stand-out growth name, rising 68% year-to-date to be exact. Even though shares have stumbled in the last week, several top analysts cite the online advertising marketplace as a force to be reckoned with.According to its third quarter results, it’s clear why TTD is on Wall Street’s radar. The company surpassed the consensus estimates for both revenue and earnings as well as upped its guidance for the fourth quarter. While this guidance was disappointing for some investors, SunTrust Robinson analyst Youssef Squali argues that TTD is holding up well against the expanding total available market and has been steadily improving margins. Squali also highlights TTD based on its stellar 95%-plus customer retention rate in the quarter as well as its continued efforts to capitalize on international opportunities and a more-data driven approach from agencies and brands. Meanwhile, RBC Capital’s Mark Mahaney believes that TTD is “one of the best positioned stocks to benefit from the shift to streaming” thanks to its rapidly growing connected TV (CTV) segment. The CTV business has grown about 145% year-over-year following many previous quarters of triple digit growth rates. “We estimate CTV to account for close to 20% of TTD’s Revenue in 2020 – and the recent deal with Amazon Fire TV / APS is further evidence of their strong positioning,” he noted. Bearing this in mind, both of the five-star analysts maintain a bullish thesis. Out of the two, Squali sees the largest potential twelve-month gain, with the forecast coming in at 46%. (To watch Squali’s track record, click here) In general, other analysts are on the same page. 6 Buy ratings and 2 Holds assigned in the last three months add up to a ‘Strong Buy’ consensus. The average price target of $247 brings the upside potential to 26%. (See Trade Desk stock analysis on TipRanks) Catalent Inc. (CTLT)Catalent is known for providing integrated services, superior drug delivery technologies and manufacturing solutions to help launch pharmaceuticals, biologics and other consumer health products. With it starting off its fiscal year on a positive note and its shares already up 59% year-to-date, the Street has its eye on CTLT.CTLT’s solid fiscal Q1 2020 performance, which included a 2% EBITDA beat and 11% organic growth, was fueled largely by its Paragon acquisition. In addition, management reaffirmed ibuprofen supply stability for Softgel by pointing out that it has alternative sources to mitigate any possible disruptions in the future. It should also be noted that its strength in the oral drug delivery business stands to drive significant gains for CTLT. All of this played into UBS analyst Daniel Brennan’s conclusion that the company is in it for the long-haul. While acknowledging the tempered stock reaction to these developments, he remains optimistic about CTLT’s prospects. “We see the lack of share price reaction as an opportunity to reiterate our buy rating,” Brennan explained. Along with his Buy rating, the analyst set a $66 price target. Based on this target, shares could surge 33% over the next twelve months. (To watch Brennan’s track record, click here) Similarly, the rest of the Street likes what it’s seeing. With 4 Buy ratings compared to 1 Hold issued in the last three months, CTLT has a ‘Strong Buy’ analyst consensus. On top of this, its $61 average price target implies 23% upside potential. (See Catalent stock analysis on TipRanks)
- Zacks
Catalent (CTLT) Surpasses Q1 Earnings and Revenue Estimates
Catalent (CTLT) delivered earnings and revenue surprises of 8.33% and 4.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
